CR Boya Bio-pharmaceutical’s Mixed Mid-Year Financials

China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.

China Resources Pharmaceutical Group’s subsidiary, CR Boya Bio-pharmaceutical, has reported a decrease in revenue by 41.87% and a slight decline in net profit of 3.05% for the first half of 2024, but an increase in total assets and net assets by 2.48% and 2.25%, respectively. The financial performance indicates challenges in revenue and net cash flow, which has dropped significantly by 46.17%, while there’s a marginal improvement in net profit after extraordinary items.

For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.